Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
4(40%)
Results Posted
33%(2 trials)

Phase Distribution

Ph phase_1
3
30%
Ph phase_2
3
30%
Ph early_phase_1
1
10%
Ph not_applicable
2
20%
Ph phase_3
1
10%

Phase Distribution

4

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Early Phase 1First-in-human
1(10.0%)
Phase 1Safety & dosage
3(30.0%)
Phase 2Efficacy & side effects
3(30.0%)
Phase 3Large-scale testing
1(10.0%)
N/ANon-phased studies
2(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

10

all time

Status Distribution
Active(4)
Completed(6)

Detailed Status

Completed6
Recruiting3
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
4
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (10.0%)
Phase 13 (30.0%)
Phase 23 (30.0%)
Phase 31 (10.0%)
N/A2 (20.0%)

Trials by Status

completed660%
recruiting330%
active_not_recruiting110%

Recent Activity

4 active trials
Showing 5 of 10
completedearly_phase_1

Brain Amyloid- Retention During Wakefulness and Following Emergence From Sleep in Healthy People

NCT02669225
recruitingphase_1

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

NCT07169630
completedphase_3

Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis

NCT05184088
recruitingphase_2

Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease

NCT04576793
recruitingphase_1

PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease

NCT04396873
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT02669225Early Phase 1

Brain Amyloid- Retention During Wakefulness and Following Emergence From Sleep in Healthy People

Completed
NCT07169630Phase 1

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

Recruiting
NCT05184088Phase 3

Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis

Completed
NCT04576793Phase 2

Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease

Recruiting
NCT04396873Phase 1

PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease

Recruiting
NCT04840979Phase 2

Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimer's Disease

Active Not Recruiting
NCT04392960Not Applicable

Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis

Completed
NCT03706261Phase 1

Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults

Completed
NCT02831283Phase 2

Imaging Inflammation in Alzheimer's Disease

Completed
NCT03779815Not Applicable

Detection of Amyloidosis in Multiple Myeloma Patients by [18F]Florbetaben Positron Emission Tomography

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10